Want to see WHWK full AI Analyst Report?

Whitehawk Therapeutics (WHWK) Earnings Dates, Call Summary & Reports

501 Followers

Earnings Data

Report Date

Aug 12, 2026

Before Open (Confirmed)

Period Ending

2026 (Q2)

Consensus EPS Forecast

-0.31

Last Year’s EPS

-0.76

Same Quarter Last Year

Analyst Consensus

Moderate Buy

Based on 6 Analysts Ratings

Earnings Call Summary

Q4 2024

Earnings Call Date:Mar 18, 2025|

% Change Since:

Earnings Call Sentiment|Positive

The earnings call reflects a positive sentiment with significant strategic transformations, a promising pipeline of ADC therapies, and strong financial positioning. However, there are concerns about increased R&D expenses and net losses, which are common in early biotech transitions.

Company Guidance

In the earnings call for the fourth quarter and full year 2024, Whitehawk Therapeutics provided guidance on their transformative shift from Aadi Biosciences to an ADC-focused company. The key metrics highlighted include a $100 million PIPE financing and the divestiture of FYARRO, which resulted in a financial position of $170 million to $180 million in cash and equivalents, expected to fund operations into 2028. The company reported FYARRO net product sales of $7.2 million for the fourth quarter, marking a 14% increase from the previous year, and $26 million for the full year, a 7% rise from 2023. Research and development expenses increased to $14.3 million for the quarter and $51 million for the year, primarily due to ADC program acquisitions. Whitehawk plans to file three Investigational New Drug (IND) applications within 15 months for their ADC candidates, targeting PTK7, MUC16, and SEZ6, with anticipated Phase 1 trials in several high-potential cancer indications.

Transformation and Strategic Transactions

Whitehawk Therapeutics was launched from Aadi Biosciences, including in-licensing 3 ADCs from Wuxi Biologics, divestiture of FYARRO to Kaken Pharmaceuticals, and $100 million pipe financing, approved by stockholders.

Advanced ADC Platform

Whitehawk is rapidly progressing a multi-asset portfolio of advanced ADC therapy, leveraging a platform with minimal off-target toxicity, greater stability, and higher therapeutic index compared to first-generation predecessors.

Financial Position

Ended 2024 with $47.2 million in cash and expect $170-$180 million after transactions, funding operations into 2028.

FYARRO Sales Growth

FYARRO net product sales were $7.2 million for Q4, representing 14% growth over the prior year quarter. Full-year sales were $26 million, an increase of 7% over 2023.

Whitehawk Therapeutics (WHWK) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

WHWK Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 12, 2026	2026 (Q2)	-0.31 / -	-0.76	―	―	―
May 07, 2026	2026 (Q1)	-0.36 / -0.32	1.83	-117.49% (-2.15)	―	―
Mar 12, 2026	2025 (Q4)	-0.48 / -0.34	-0.67	49.25% (+0.33)	―	―
Nov 06, 2025	2025 (Q3)	0.07 / -0.26	-0.46	43.48% (+0.20)	―	―
Aug 07, 2025	2025 (Q2)	0.82 / -0.76	-0.54	-40.74% (-0.22)	―	―
May 08, 2025	2025 (Q1)	-0.46 / 1.83	-0.68	369.12% (+2.51)		―
Mar 18, 2025	2024 (Q4)	-0.29 / -0.67	-0.6	-11.67% (-0.07)	―
Nov 06, 2024	2024 (Q3)	-0.46 / -0.46	-0.6	23.33% (+0.14)	―	―
Aug 07, 2024	2024 (Q2)	-0.69 / -0.54	-0.67	19.40% (+0.13)	―
May 08, 2024	2024 (Q1)	-0.62 / -0.68	-0.57	-19.30% (-0.11)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

WHWK Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 07, 2026	$4.15	$3.94	-5.06%
Mar 12, 2026	$4.01	$3.90	-2.74%
Nov 06, 2025	$2.25	$2.10	-6.67%
Aug 07, 2025	$1.80	$1.72	-4.44%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Whitehawk Therapeutics (WHWK) report earnings?

Whitehawk Therapeutics (WHWK) is schdueled to report earning on Aug 12, 2026, Before Open (Confirmed).

What is Whitehawk Therapeutics (WHWK) earnings time?

Whitehawk Therapeutics (WHWK) earnings time is at Aug 12, 2026, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is WHWK EPS forecast?

WHWK EPS forecast for the fiscal quarter 2026 (Q2) is -0.31.